Bio-Path Hopes To Blaze Profitable Path With Antisense Drugs
Bio-Path Holdings is trying to become the next company to make it big with antisense drugs. Recently, the Houston-based biotech released data showing its lead compound, which is known as BP-1001, may hold promise in treating advanced acute myeloid leukemia, or AML.
You may also be interested in...
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.
Over the past few years, frustrating instances of shortages and recalls – particularly generics – have been blamed on inferior quality control at countless suppliers of active pharmaceutical ingredients and finished products, especially those based in India and China.
In case you have not noticed, a new gold rush appears to be under way. Buoyed by surging interest in medical cannabis, big and small companies from around the world are racing to take advantage of the potential for the marijuana plant to cure numerous diseases and take its place in the pantheon of pharmaceutical products.